Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss

Female Pattern Hair Loss Clinical Trial

Official title:

Efficacy of Therapy With the Anti-androgen Spironolactone Compared to Topical Minoxidil in Female Pattern Hair Loss

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00175617
• Other study ID #: C05-0060
• Status: Completed
• Phase: Phase 2
• First received: September 13, 2005
• Last updated: March 1, 2017
• Start date: September 2005
• Est. completion date: March 9, 2009

Study information

• Verified date: March 2017
• Source: University of British Columbia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 9, 2009
• Est. primary completion date: March 9, 2009
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects must be premenopausal women older than 18 with female pattern hair loss.

Exclusion Criteria:

• Androgen excess

• Other scalp or hair disorders

• Contraindications to spironolactone treatment, especially pregnancy, electrolyte imbalances, history of breast cancer, or intake of interfering drugs

• Contraindications to minoxidil treatment, especially patients who are allergic to this treatment or have a history of low blood pressure or irregular heart beats

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata
• Female Pattern Hair Loss

Intervention

Drug:
• Spironolactone
This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
• Minoxidil
This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.

Locations

Country	Name	City	State
Canada	UBC Division of Dermatology, Hair Research and Treatment Centre	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	hair density		after 3, 6 and 9 months
Secondary	percentage of subjects who experience side effects		Unspecified
Secondary	subject assessment of treatment effect		Unspecified